Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2011 / Cilt: 20 - Sayı: 1

Intravenous Iron Treatment in patients with chronic renal disease, oxidative stress and the effect of N-acetylcysteine

Kronik böbrek hastalarında intravenöz demir tedavisi, oksidatif stres ve N-asetilsistein'in etkisi

Pages
65–71
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The decrease in CAT levels was prevented with NAC pre-treatment but GPx levels decreased significantly and SOD levels also did not change from the baseline.CONCLUSION: Our study shows that IV iron therapy in CRD changes some oxidative stress parameters.600 mg/d NAC pre-treatment dose not increase the antioxidant effect of IV iron therapy significantly.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: One of the problems in treating anemia of CRD is iron deficiency, and intravenous (IV) iron supplementation has become an accepted therapy of iron deficiency in CRD patients.
📊
Key Findings & Data:However, it is known that free iron is prooxidant and causes oxidative stress by generation of hydroxyl radicals through the fenton reaction.The purpose of this study was to determine the relationship between IV iron treatment and oxidative stress, and to determine the effect of N-acetylcysteine (NAC), which is an antioxidant, on this possible oxidative stress.MATERIAL and METHOD: 30 patients with iron deficiency anemia and CRD (stage3-5 according to K/DOQI) scheduled to receive IV iron treatment were separated into two groups.
💡
Conclusion & Impact:The decrease in CAT levels was prevented with NAC pre-treatment but GPx levels decreased significantly and SOD levels also did not change from the baseline.CONCLUSION: Our study shows that IV iron therapy in CRD changes some oxidative stress parameters.600 mg/d NAC pre-treatment dose not increase the antioxidant effect of IV iron therapy significantly.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: One of the problems in treating anemia of CRD is iron deficiency, and intravenous (IV) iron supplementation has become an accepted therapy of iron deficiency in CRD patients. However, it is known that free iron is prooxidant and causes oxidative stress by generation of hydroxyl radicals through the fenton reaction.The purpose of this study was to determine the relationship between IV iron treatment and oxidative stress, and to determine the effect of N-acetylcysteine (NAC), which is an antioxidant, on this possible oxidative stress.MATERIAL and METHOD: 30 patients with iron deficiency anemia and CRD (stage3-5 according to K/DOQI) scheduled to receive IV iron treatment were separated into two groups. One group received only IV iron, and the other group received NAC orally beside IV iron treatment. Malondialdehyde (MDA), glutathione peroxidase (GPx),catalase (CAT) and superoxide dismutase (SOD) levels were measured to determine oxidative stress in each group.RESULTS: The antioxidant enzyme levels of erythrocyte Glutathion peroxidase (GPx) and catalase (CAT) decreased significantly but erythrocyte superoxide dismutase (SOD) activity did not change in the IV iron treatment group. The decrease in CAT levels was prevented with NAC pre-treatment but GPx levels decreased significantly and SOD levels also did not change from the baseline.CONCLUSION: Our study shows that IV iron therapy in CRD changes some oxidative stress parameters.600 mg/d NAC pre-treatment dose not increase the antioxidant effect of IV iron therapy significantly.

Özet

AMAÇ: Kronik Böbrek Hastalığında (KBH) anemi tedavisinde görülen önemli bir sorun da demir eksikliğidir ve IV demir replasmanı bu amaçla sık kullanılmaktadır. Ancak, serbest demirin prooksidan olduğu ve fenton reaksiyonu yoluyla hidroksil radikalleri oluşturarak oksidatif strese (OS) ve endotel disfonksiyonuna (ED) sebep olduğu ileri sürülmektedir. Bu çalışmanın amacı, IV demir tedavisi ile OS arasındaki ilişkiyi ve bir antioksidan olan N-asetilsistein (NAC)'in oluşabilecek bu OS üzerine etkisini değerlendirmektir.GEREÇ ve YÖNTEM: K/DOQI rehberi kriterlerine göre Evre 3-5 KBH tanısı konulan ve anemi saptanan 30 hasta çalışmaya alınmıştır. Demir eksikliği nedeniyle IV demir verilmesi planlanan hastalar iki gruba ayrılmış, bir gruba yalnızca parenteral demir verilirken, diğer gruba parenteral demirin yanısıra NAC de verilmiştir. Her iki grupta da oksidatif stresi değerlendirmek amacı ile malondialdehit (MDA), glutatyon peroksidaz (GPx), katalaz (CAT) ve süperoksit dismutaz (SOD) düzeyleri incelenmiştir.BULGULAR: Çalışmamızda parenteral demir tedavisi alan grupta antioksidan savunma göstergeleri olan GPx ve CAT düzeylerinde azalma olurken SOD düzeylerinde değişiklik olmadı. Demir tedavisine NAC'in eklenmesi ile CAT düzeylerindeki azalmanın önüne geçilirken GPx düzeyindeki azalmanın önüne geçilememiştir. Ayrıca NAC tedavisi SOD düzeylerini ve MDA düzeylerini anlamlı düzeylerde değiştirmemiştir.SONUÇ: Kronik böbrek hastalarında IV demir tedavisi bazı oksidatif stres göstergelerinde değişikliğe yol açmaktadır. IV demir tedavisine eklenen 600 mg/gün NAC katalaz düzeyindeki azalmanın önüne geçse de belirgin antioksidan etki oluşturmamaktadır.

🔖

Cite This Article

ÜNAL, H. U., SAĞLAM, K., EKEN, A., KARAMAN, M., ÇAĞLAR, K., AÇIKEL, C., SAKİN, Y. S., AY, S. A., AKAY, C., ÇAKIR, E. (2022). Intravenous Iron Treatment in patients with chronic renal disease, oxidative stress and the effect of N-acetylcysteine. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 20 - Sayı: 1, 65–71. https://ajindex.com/articles/636430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kooistra MP, van Es A, Struyvenberg A, Marx JJ: Iron metabolism in patients with anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991
  2. 639 2. Baykal Y, Yılmaz MI, Çelik T, Gök F, Rehber H, Akay C, Koçar IH: Effects of antihypertensive agents, alpha receptor blockers, beta blockers angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stres. J Hypertens 2003
  3. 1211 3. Ertan T, Soran A: Kan malonilaldehit ve total antioksidan seviyenin önemi. Cerrahi Tıp Bülteni 2001
  4. 167 4. Andrews NP, Prasad A, Quyyumi AA: N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001
  5. 123 5. Kletzmayr J, Hörl WH: Iron overload and cardiovascular complications in dialysis patients. Neprol Dial Transplant 2002
  6. 29 6. Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A: Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009
  7. 15(26): 2988-3002 7. Rachmilewitz EA, Weizer-Stern O, Breda L, Adamsky K, Amariglio N, Rechavi G, Rivella S, Cabantchik L: Role of iron in inducing oxidative stres in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants? Ann N Y Acad Sci 2005
  8. 123 8. Mimić-Oka J, Savić-Radojević A, Pljesa-Ercegovac M, Opacić M, Simić T, Dimković N, Simić DV: Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail 2005
  9. 351 9. Lim PS, Wei YH, Yu YL, Kho B: Enhanced Oxidative stress in hemodialysis patients recieving intravenous iron therapy. Nephrol Dial Transplant 1999
  10. 2687 10. Roob M, Khoshsorur G,Tiran A, Horina JH, Holzer H, Winklhoffer Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000
  11. 549 11. Cavdar C, Temiz A Cavdar C, Temiz A, Yeniçerioğlu Y, Calişkan S, Celik A, Sifil A, Onvural B, Camsari T: The effects of intravenous iron treatment on oxidant stress and erythroyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003: 37: 77-82 12. Agarwal R, Vasavada N, Sachs N, Chase S: Oxidative stress and renal injury with intravenous iron in patiens with chronic kidney disease. Kidney Int 2004
  12. 2289 13. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoc